To confirm that the underlying mechanism of therapeutic action of this practical clinical intervention pivoted on the expression of SP-B, we showed that adding rSP-B alone to SP-B-mutant DLOs similarly reduced infection and cell death at 36 and 54 hpi (Fig. 6 H and I). This evidence concerns the gene SFTPB and infection.